Insulet price target raised to $330 from $325 at RBC Capital
TipRanks
May. 9, 2025, 07:13 AM
RBC Capital analyst Shagun Singh raised the firm’s price target on Insulet (PODD) to $330 from $325 and keeps an Outperform rating on the shares. The company delivered record Q1 sales with worldwide growth of about 30%, and its 2025 guide is still notably conservative, positioning Insulet for upside, the analyst tells investors in a research note.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
Disclaimer & DisclosureReport an Issue
- Insulet price target raised to $330 from $310 at BTIG
- Insulet’s Strong Growth and Strategic Expansion Under New Leadership
- Insulet’s Strong Financial Performance and Growth Potential Drive Buy Rating
- Insulet’s Strong Financial Performance and Promising Future: A Buy Recommendation by Josh Jennings
- Insulet Corporation Reports Strong Q1 2025 Growth
